Cellectis ADR (CLLS)

전일 마감가:

$3.35

열려 있는:

$3.07

하루 거래량:

97,738

시가총액:

$241.04M

수익:

$16.50M

순이익/손실:

$-85.02M

주가수익비율:

-1.4899

EPS:

-1.99

순현금흐름:

$-66.74M

1주 성능:

+16.02%

1개월 성능:

+10.82%

6개월 성능:

+24.27%

1년 성능:

+56.32%

1일 변동 폭

$2.94

$3.07

52주 변동 폭

$0.9628

$3.7735

Cellectis ADR Stock (CLLS) Company Profile

명칭

Cellectis ADR

부문

Healthcare (1219)

산업

Biotechnology (700)

전화

33 1 81 69 16 00

주소

8, rue de la Croix Jarry, Paris

직원

131

트위터

@cellectis

다음 수익 날짜

2024-05-13

최신 SEC 제출 서류

CLLS's Discussions on Twitter

Cellectis ADR Stock (CLLS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-03-17	개시	Bryan Garnier	Buy
2022-05-18	업그레이드	Robert W. Baird	Neutral → Outperform
2022-01-06	다운그레이드	Wells Fargo	Overweight → Equal Weight
2021-11-30	개시	JMP Securities	Mkt Outperform
2021-11-08	다운그레이드	William Blair	Outperform → Mkt Perform
2021-10-08	다운그레이드	Robert W. Baird	Outperform → Neutral
2021-04-28	다운그레이드	Guggenheim	Buy → Neutral
2021-03-16	업그레이드	Robert W. Baird	Neutral → Outperform
2020-08-19	업그레이드	Citigroup	Neutral → Buy
2020-05-12	개시	Robert W. Baird	Outperform
2020-03-06	다운그레이드	Goldman	Neutral → Sell
2019-10-30	재개	Guggenheim	Buy
2019-08-09	개시	BTIG Research	Buy
2019-05-24	재개	Citigroup	Neutral
2019-03-14	개시	William Blair	Outperform
2018-12-19	개시	Goldman	Neutral
2018-07-16	개시	Barclays	Overweight
2018-03-16	개시	Guggenheim	Neutral
2017-09-05	다운그레이드	SunTrust	Buy → Hold
2017-09-05	재확인	Wells Fargo	Outperform
2017-03-02	개시	Instinet	Buy
2017-02-28	개시	Wells Fargo	Outperform
2016-04-05	개시	Ladenburg Thalmann	Buy
2016-03-02	개시	Sun Trust Rbsn Humphrey	Buy
2015-07-20	개시	BofA/Merrill	Buy
2015-04-20	개시	Jefferies	Buy
2015-04-20	개시	Piper Jaffray	Overweight

모두보기

Cellectis ADR 주식(CLLS)의 최신 뉴스

Monthly information on share capital and company voting rights

GlobeNewswire Inc.

Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca

GlobeNewswire Inc.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire Inc.

Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 

GlobeNewswire Inc.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

GlobeNewswire Inc.

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

GlobeNewswire Inc.

Cellectis ADR (CLLS) 재무 분석

Cellectis ADR (CLLS) 매출 2024

Cellectis ADR (CLLS) 순이익 2024

Cellectis ADR (CLLS) 현금흐름 2024

Cellectis ADR (CLLS) 주당 순이익 2024